Tivic Health Systems (NASDAQ:TIVC) stock is rocketing higher on Thursday after getting started on a new clinical trial.
According to a press release from the company, its study at The Feinstein Institutes for Medical Research has been given approval by the Institutional Review Board. As a result, the company has started recruitment and enrollment for the trial.
The study Tivic Health Systems is conducting is connected to the vagus nerve. The company intends to use a non-invasive bioelectronic device to promote stimulation of the nerve. This pilot study will be conducted with the help of 20 people.
Jennifer Ernst, CEO of Tivic Health Systems, said this about the news:
“We’re excited for the proprietary value this work has the potential to deliver, as we continue to explore expanding Tivic’s non-invasive bioelectronic solutions to vagus nerve pathways and other clinical uses.”
TIVC Stock Movement Today
Investors will also note that shares of TIVC stock are seeing incredibly strong movement on Thursday. As of this writing, more than 57 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is about 24 million shares.
It’s also worth keeping in mind that this builds on some strong stock movement yesterday. That saw some 327 million shares of the stock traded on Wednesday. With that came an 80% rally in the company’s shares.
As for Thursday, the stock is up 44.6% this morning.
Investors looking for more of the most recent stock market news will want to keep reading!
InvestorPlace is home to all of the hottest stock market news for Thursday! That includes the biggest pre-market stock movers this morning, the latest news concerning Nio (NYSE:NIO), and more. You can catch up on all of that at the links below!
More Thursday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
- 5 Investors Betting Big on Nio (NIO) Stock in Q2
- YELL Stock: Nasdaq Suspends Trading in Yellow
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
